You have 9 free searches left this month | for more free features.

RET Inhibitor

Showing 1 - 25 of 7,520

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

NSCLC Trial in Shanghai (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 4, 2023

NSCLC, Thyroid Tumors Trial (LOXO-260)

Temporarily not available
  • Carcinoma, Non-Small-Cell Lung
  • Thyroid Neoplasms
  • (no location specified)
Sep 20, 2022

Advanced Solid Tumor Trial (HEC169096)

Not yet recruiting
  • Advanced Solid Tumor
  • (no location specified)
Jul 6, 2022

Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory

Recruiting
  • Advanced Malignant Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Malignant Thyroid Gland Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma Trial in Houston

Recruiting
  • Malignant Thyroid Gland Neoplasm
  • +6 more
  • Quality-of-Life Assessment
  • +3 more
  • Ann Arbor, Michigan
  • +1 more
Jan 24, 2023

Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Tampa

Recruiting
  • Lung Non-Small Cell Carcinoma
  • +4 more
  • Tampa, Florida
    Moffitt Cancer Center
Aug 16, 2022

Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

Not yet recruiting
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • Amivantamab 1050mg
  • +2 more
  • Aurora, Colorado
  • +2 more
Apr 25, 2023

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

Advanced Solid Tumor Trial in Los Angeles (EP0031)

Recruiting
  • Advanced Solid Tumor
  • Los Angeles, California
  • +3 more
Dec 1, 2022

Advanced Malignant Tumor, BRAF Gene Mutation, Metastatic Malignant Tumor Trial in Houston (Crizotinib, Laboratory Biomarker

Completed
  • Advanced Malignant Neoplasm
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2021

NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

Recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Scottsdale, Arizona
  • +84 more
Oct 10, 2022

Breast Cancer Trial in Singapore (Lenvatinib + Letrozole, Fulvestrant)

Not yet recruiting
  • Breast Cancer
  • Singapore, Singapore
    Nationa University Hospital
Jan 4, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +37 more
  • Birmingham, Alabama
  • +171 more
Aug 24, 2022

NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Shanghai, Shanghai, China
  • +1 more
Mar 17, 2022

Non Small Cell Lung Cancer Trial in United States (Ponatinib)

Completed
  • Non Small Cell Lung Cancer
  • Orange, California
  • +4 more
Dec 8, 2019

Malignant Tumor Trial in Ann Arbor, Columbus (ponatinib HCl, laboratory biomarker analysis)

Unknown status
  • Malignant Neoplasm
  • ponatinib hydrochloride
  • laboratory biomarker analysis
  • Ann Arbor, Michigan
  • +1 more
Feb 14, 2020

Medullary Thyroid Cancer Trial in Worldwide (Selpercatinib, Cabozantinib, Vandetanib)

Recruiting
  • Medullary Thyroid Cancer
  • Birmingham, Alabama
  • +148 more
Jan 18, 2023

NSCLC, NSCLC Metastatic, NSCLC Recurrent Trial in Worldwide (Alectinib)

Terminated
  • Non-small Cell Lung Cancer
  • +2 more
  • Brussels, Belgium
  • +18 more
Aug 23, 2022

Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

Recruiting
  • Nonsmall Cell Lung Cancer
  • HS-10365 capsules
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 22, 2023

Metastatic Sporadic Medullary Thyroid Cancer Patients and

Completed
  • Metastatic Sporadic Medullary Thyroid Cancer
    • Milano, Italy
      Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    Sep 29, 2021

    Irritable Bowel Syndrome Trial in Adelaide (GSK3352589, Matching Placebo)

    Completed
    • Irritable Bowel Syndrome
    • Adelaide, South Australia, Australia
      GSK Investigational Site
    Jun 28, 2019

    Healthy Trial in Madison (Selpercatinib, Ranitidine, Omeprazole)

    Completed
    • Healthy
    • Madison, Wisconsin
      Covance Clinical Research Unit, Inc.
    Jan 12, 2023

    Non Small Cell Lung Cancer Trial in Seoul (Vandetanib)

    Completed
    • Non Small Cell Lung Cancer
    • Seoul, Korea, Republic of
    • +1 more
    Dec 4, 2020

    Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer Trial in Singapore (Oral lenvatinib + Intravenous (IV)

    Not yet recruiting
    • Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    • Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
    • Singapore, Singapore
      National Cancer Centre Singapore
    Oct 13, 2022